Cargando…

P1078: PATIENTS WITH HODGKIN LYMPHOMA DEVELOP ADEQUATE HUMORAL SEROLOGICAL RESPONSE TO VACCINATION WITH TWO DOSES OF BNT162B2 AND THEIR IGG ANTIBODY LEVELS MARKEDLY INCREASE AFTER A THIRD VACCINE DOSE

Detalles Bibliográficos
Autores principales:	Dann, E., Inbar, T., Mashiach, T., Eisa, J., Ringelstein-Harlev, S., Horowitz, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429258/ http://dx.doi.org/10.1097/01.HS9.0000847180.34574.50

Ejemplares similares

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
por: Gurion, Ronit, et al.
Publicado: (2021)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
por: Gurion, R., et al.
Publicado: (2022)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Henig, Israel, et al.
Publicado: (2023)

1078 Risk Factors Associated with Developing Fever Following First Dose Measles-Containing Vaccines
por: Klein, Nicola P., et al.
Publicado: (2014)

Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Lukaszuk, Krzysztof, et al.
Publicado: (2021)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan
por: Nishikimi, Akihiko, et al.
Publicado: (2023)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose
por: Mangia, Alessandra, et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
por: Kobashi, Yurie, et al.
Publicado: (2022)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
por: Prusinkiewicz, Martin A., et al.
Publicado: (2023)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

Humoral immune response in healthcare workers after two doses of a BNT162b2 mRNA vaccine in Yucatan, Mexico
por: Figueroa‐Hurtado, Esperanza, et al.
Publicado: (2022)

Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational Study
por: Herzberg, Jonas, et al.
Publicado: (2022)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
por: Renia, Laurent, et al.
Publicado: (2022)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1dl40rotrit8cd44chmkhhgbid